HanchorBio Inc (TPEx:7827), a Taiwan-based global clinical-stage biotechnology company, announced on Wednesday that it will present preclinical data on HCB301, a novel tri-specific immunotherapeutic fusion protein, at the 40th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) scheduled from 5-9 November 2025 in National Harbor, Maryland.

According to HanchorBio, the data highlight HCB301's differentiated design and multi-pronged antitumour mechanism, which engages both innate and adaptive immunity.

HCB301 is designed to simultaneously block SIRP alpha-CD47 interaction to enable macrophage-mediated phagocytosis and also block PD-1-PD-L1 signalling to restore exhausted T-cell function. It also traps TGF beta to overcome stromal and immune exclusion in the tumour microenvironment. This approach aims to overcome the limitations of existing checkpoint inhibitors by activating both arms of the immune system, especially in tumours with immunologically 'cold' or suppressive tumour microenvironments resistant to current treatments.

Scott Liu, PhD, HanchorBio founder, chairman, and CEO, said: "HCB301 builds directly on the foundation of HCB101, our clinical-stage SIRP alpha-engineered fusion protein. By integrating PD-1 blockade and TGF beta neutralisation into a single molecule, HCB301 represents what we believe to be the first-in-class tri-specific fusion protein that simultaneously targets immune checkpoints, immune suppression, and macrophage dysfunction. This design reflects our commitment to building modular, next-generation immunotherapies with global translation potential. With IND clearance and first-patient dosing now achieved in both the US and China, HCB301 demonstrates the scalability of our FBDB platform and the executional readiness of our team across regions. As we advance HCB301 into the clinical stage, this milestone further positions HanchorBio as a long-term innovation partner for global co-development, particularly in cancers with high resistance to conventional immunotherapies."